

Blockade of the checkpoint receptor TIGIT prevents NK anti-tumor immunity

Nature Immunology

19, 723-732

DOI: [10.1038/s41590-018-0132-0](https://doi.org/10.1038/s41590-018-0132-0)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells. Chinese Journal of Natural Medicines, 2018, 16, 907-915.	0.7	25
3	Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. International Journal of Molecular Sciences, 2018, 19, 3648.	1.8	32
4	CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11731-E11740.	3.3	36
5	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93.	3.6	121
6	The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45.	4.8	67
7	Thinking differently about <sc>ILC</sc>”Not just tissue resident and not just the same as <sc>CD</sc>4⁺ T cell effectors. Immunological Reviews, 2018, 286, 160-171.	2.8	24
8	Dormant tumour cells, their niches and the influence of immunity. Nature Cell Biology, 2018, 20, 1240-1249.	4.6	134
9	Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals. Frontiers in Immunology, 2018, 9, 2341.	2.2	48
10	KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in HLA-B Bw4 Homozygous Individuals. Frontiers in Immunology, 2018, 9, 1855.	2.2	8
11	Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	105
12	Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunology, 2018, 18, 671-688.	10.6	702
13	Checkpoint inhibition: NK cells enter the scene. Nature Immunology, 2018, 19, 650-652.	7.0	18
14	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 2019, 178, 933-948.e14.	13.5	301
15	Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma. Cancer Immunology Research, 2019, 7, 1700-1713.	1.6	126
16	Development of cMET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Molecular Medicine Reports, 2019, 20, 2823-2831.	1.1	28
17	DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?. International Journal of Molecular Sciences, 2019, 20, 3715.	1.8	34
18	Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9. Immunology, 2019, 158, 63-69.	2.0	45
19	DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers, 2019, 11, 877.	1.7	151

#	ARTICLE	IF	CITATIONS
20	Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1. <i>Journal of Biological Chemistry</i> , 2019, 294, 12534-12546.	1.6	13
21	NK Cell-Based Immunotherapy for Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1702.	1.0	54
22	NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 416.	3.5	25
23	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	1.8	39
24	Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. , 2019, 7, 259.		10
25	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz022.	0.4	16
26	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019, 18, 155.	7.9	723
27	The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2354.	2.2	70
28	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1782.	2.2	45
29	NK Cell Dysfunction and Checkpoint Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1999.	2.2	105
30	Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2019, 104, 102333.	3.0	70
31	Negative regulation of innate lymphoid cell responses in inflammation and cancer. <i>Immunology Letters</i> , 2019, 215, 28-34.	1.1	10
32	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. <i>Frontiers in Immunology</i> , 2019, 10, 1415.	2.2	57
33	Activating KIRs on Educated NK Cells Support Downregulation of CD226 and Inefficient Tumor Immunosurveillance. <i>Cancer Immunology Research</i> , 2019, 7, 1307-1317.	1.6	8
34	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 874.	1.7	85
36	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
37	Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. <i>Frontiers in Immunology</i> , 2019, 10, 1205.	2.2	292
38	Stress-elicited glucocorticoid receptor signaling upregulates TIGIT in innate-like invariant T lymphocytes. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 793-804.	2.0	20

#	ARTICLE	IF	CITATIONS
39	Human natural killer cells mediate adaptive immunity to viral antigens. <i>Science Immunology</i> , 2019, 4, .	5.6	135
40	Treg-mediated acquired resistance to immune checkpoint inhibitors. <i>Cancer Letters</i> , 2019, 457, 168-179.	3.2	148
41	Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2057.	1.8	17
42	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. <i>Frontiers in Immunology</i> , 2019, 10, 910.	2.2	54
43	Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. <i>International Immunopharmacology</i> , 2019, 72, 374-384.	1.7	109
44	Natural killer cells as a promising therapeutic target for cancer immunotherapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 591-606.	2.7	29
45	Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture). <i>Hla</i> , 2019, 93, 185-194.	0.4	11
46	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17
47	From the "missing self" hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance. <i>Journal of Leukocyte Biology</i> , 2019, 105, 955-971.	1.5	23
48	Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. <i>Frontiers in Immunology</i> , 2019, 10, 9.	2.2	126
49	Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects. <i>Engineering</i> , 2019, 5, 106-114.	3.2	30
50	T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis. <i>International Immunopharmacology</i> , 2019, 70, 428-434.	1.7	52
51	Mutually assured destruction: the cold war between viruses and natural killer cells. <i>Current Opinion in Virology</i> , 2019, 34, 130-139.	2.6	20
52	Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. <i>Frontiers in Immunology</i> , 2019, 10, 877.	2.2	81
53	The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis. <i>Frontiers in Endocrinology</i> , 2019, 10, 145.	1.5	10
54	NKG2A is a NK cell exhaustion checkpoint for HCV persistence. <i>Nature Communications</i> , 2019, 10, 1507.	5.8	109
55	Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. <i>Cancers</i> , 2019, 11, 461.	1.7	119
56	Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 861-870.	2.0	49

#	ARTICLE	IF	CITATIONS
57	CRTAM+ NK cells endowed with suppressor properties arise in leukemic bone marrow. <i>Journal of Leukocyte Biology</i> , 2019, 105, 999-1013.	1.5	12
58	Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. <i>Journal of Cancer</i> , 2019, 10, 697-707.	1.2	16
59	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. <i>Cellular and Molecular Immunology</i> , 2019, 16, 430-441.	4.8	327
60	Human liver-derived CXCR6+NK cells are predominantly educated through NKG2A and show reduced cytokine production. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1331-1340.	1.5	20
61	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 51.	1.3	117
62	Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling. <i>Cancer Research</i> , 2020, 80, 1130-1142.	0.4	89
63	Liver-Mediated Adaptive Immune Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 2525.	2.2	125
64	Harnessing NK Cells for Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 2836.	2.2	66
65	Harnessing innate immunity in cancer therapy. <i>Nature</i> , 2019, 574, 45-56.	13.7	533
66	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	1.0	29
67	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
68	NK Cell-Based Immunotherapy in Cancer Metastasis. <i>Cancers</i> , 2019, 11, 29.	1.7	82
69	Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 168-183.	3.6	209
70	The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 142-158.	2.9	218
71	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 861-867.	2.0	36
72	Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. <i>Nature Communications</i> , 2019, 10, 221.	5.8	54
73	Acute myeloid leukemia and NK cells: two warriors confront each other. <i>Oncolmmunology</i> , 2019, 8, e1539617.	2.1	27
74	Targeting PVR (CD155) and its receptors in anti-tumor therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 40-52.	4.8	110

#	ARTICLE	IF	CITATIONS
75	Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model. <i>Hepatology</i> , 2020, 71, 1297-1315.	3.6	41
76	Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. <i>Methods in Enzymology</i> , 2020, 631, 483-495.	0.4	10
77	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. <i>Seminars in Cancer Biology</i> , 2020, 65, 13-27.	4.3	170
78	Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. <i>International Journal of Cancer</i> , 2020, 146, 1421-1434.	2.3	40
79	Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells. <i>Molecular Immunology</i> , 2020, 118, 99-109.	1.0	22
80	Tumor intrinsic and extrinsic immune functions of CD155. <i>Seminars in Cancer Biology</i> , 2020, 65, 189-196.	4.3	85
81	Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 83-86.	2.4	4
82	Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. <i>Cancer Letters</i> , 2020, 470, 126-133.	3.2	753
83	TIGIT as an emerging immune checkpoint. <i>Clinical and Experimental Immunology</i> , 2020, 200, 108-119.	1.1	310
84	Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection. <i>Viral Immunology</i> , 2020, 33, 334-341.	0.6	17
85	Promising approaches in cancer immunotherapy. <i>Immunobiology</i> , 2020, 225, 151875.	0.8	49
86	Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584099.	2.2	20
87	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
88	NK cells and ILCs in tumor immunotherapy. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100870.	2.7	134
89	COVID-19 Infection: Concise Review Based on the Immunological Perspective. <i>Immunological Investigations</i> , 2020, , 1-20.	1.0	11
90	NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. <i>Seminars in Immunology</i> , 2020, 48, 101407.	2.7	31
91	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2444-2455.	0.9	7
92	Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis. <i>IScience</i> , 2020, 23, 101513.	1.9	11

#	ARTICLE	IF	CITATIONS
93	Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	8
94	Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2762.	1.7	41
95	The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/ β^2 -catenin signaling pathway. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1163-1179.	4.8	40
96	Drug target validation in primary human natural killer cells using CRISPR RNP. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1397-1408.	1.5	27
97	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 403-406.	0.8	9
98	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5034.	1.8	30
99	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
100	<p><p>Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5957-5974.	0.9	21
101	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. <i>Oncolimmunology</i> , 2020, 9, 1843247.	2.1	48
102	Multidimensional molecular controls defining NK/ILC1 identity in cancers. <i>Seminars in Immunology</i> , 2021, 52, 101424.	2.7	15
104	Adoptive natural killer cell therapy: a human pluripotent stem cell perspective. <i>Current Opinion in Chemical Engineering</i> , 2020, 30, 69-76.	3.8	3
105	Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. <i>Cancers</i> , 2020, 12, 3504.	1.7	30
106	The Immune Endocannabinoid System of the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8929.	1.8	28
107	The Tumor Microenvironmentâ€™A Metabolic Obstacle to NK Cellsâ€™™ Activity. <i>Cancers</i> , 2020, 12, 3542.	1.7	30
108	Targeting novel inhibitory receptors in cancer immunotherapy. <i>Seminars in Immunology</i> , 2020, 49, 101436.	2.7	8
109	A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580140.	1.8	10
110	Natural killer cells in cancer biology and therapy. <i>Molecular Cancer</i> , 2020, 19, 120.	7.9	344
111	A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 144-151.	1.0	28

#	ARTICLE	IF	CITATIONS
112	Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2020, 10, 1595.	1.3	33
113	Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors. <i>Frontiers in Immunology</i> , 2020, 11, 1076.	2.2	61
114	Mutant <i>KRAS</i> Promotes NKG2D ⁺ T Cell Infiltration and CD155 Dependent Immune Evasion. <i>Anticancer Research</i> , 2020, 40, 4663-4674.	0.5	6
115	Unraveling exhaustion in adaptive and conventional NK cells. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1361-1368.	1.5	30
116	Autophagy, the innate immune response and cancer. <i>Molecular Oncology</i> , 2020, 14, 1913-1929.	2.1	55
117	Make killers sweeter: targeting metabolic checkpoints of NK cells. <i>Nature Immunology</i> , 2020, 21, 970-971.	7.0	1
118	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
119	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8000.	1.8	25
120	Harnessing Natural Killer Cell Function for Genitourinary Cancers. <i>Urologic Clinics of North America</i> , 2020, 47, 433-442.	0.8	6
121	Emerging immunotherapy targets in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2456-2465.	0.9	8
122	Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. <i>Nature Cancer</i> , 2020, 1, 1097-1112.	5.7	234
123	Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 250.	7.1	86
124	Natural Killer Cells in Immunotherapy: Are We Nearly There?. <i>Cancers</i> , 2020, 12, 3139.	1.7	15
125	Study and analysis of antitumor resistance mechanism of PD1/PD-1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
126	A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. <i>Journal of Immunology</i> , 2020, 205, 2156-2168.	0.4	13
127	Escape of tumor cells from the NK cell cytotoxic activity. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1339-1360.	1.5	14
128	Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 425.	1.8	51
129	Repositioning Iloperidone for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. <i>Cell Communication and Signaling</i> , 2020, 18, 142.	2.7	18

#	ARTICLE	IF	CITATIONS
130	COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1133-1138.	1.0	10
131	TIGIT in cancer immunotherapy. , 2020, 8, e000957.		382
132	<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
133	Intratumoral TIGIT⁺ CD8⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
134	Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. <i>Blood</i> , 2020, 136, 3004-3017.	0.6	71
135	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. <i>Cell Research</i> , 2020, 30, 966-979.	5.7	349
136	Role of Natural Killer Cells in Uveal Melanoma. <i>Cancers</i> , 2020, 12, 3694.	1.7	16
137	Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. <i>Cancers</i> , 2020, 12, 3705.	1.7	10
138	Mechanisms of Immunosuppression in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3850.	1.7	30
139	Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. , 2020, 8, e001849.		40
140	Immune checkpoint markers and antiâ€CD20â€mediated NK cell activation. <i>Journal of Leukocyte Biology</i> , 2020, 110, 723-733.	1.5	2
141	Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. <i>Nature Communications</i> , 2020, 11, 6322.	5.8	259
142	NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. <i>OncImmunology</i> , 2020, 9, 1845424.	2.1	38
143	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 575609.	2.2	34
144	Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. , 2020, 8, e001355.		55
145	A Novel d â€Peptide Identified by Mirrorâ€Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2020, 132, 15226-15230.	1.6	1
146	TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 175.	1.8	13
147	A Novel <sc>d</sc>â€Peptide Identified by Mirrorâ€Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 15114-15118.	7.2	80

#	ARTICLE	IF	CITATIONS
148	Functional and metabolic targeting of natural killer cells to solid tumors. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 577-600.	2.1	25
149	Influence of Innate Immunity on Cancer Cell Stemness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3352.	1.8	20
150	Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells. <i>Cells</i> , 2020, 9, 1193.	1.8	17
151	Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 783.	2.2	78
152	CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 76.	6.9	65
153	IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2371-2380.	2.0	30
154	Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1295.	2.2	58
155	Mechanisms of immune escape in the cancer immune cycle. <i>International Immunopharmacology</i> , 2020, 86, 106700.	1.7	85
156	The cancerâ€™natural killer cell immunity cycle. <i>Nature Reviews Cancer</i> , 2020, 20, 437-454.	12.8	308
157	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 9050.	1.6	43
158	TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells. <i>Aids</i> , 2020, 34, 801-813.	1.0	40
159	Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. <i>Stem Cell Research and Therapy</i> , 2020, 11, 234.	2.4	55
160	The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2020, 159, 434-436.	0.6	5
161	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
162	Targeting Natural Killer Cells for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 60.	2.2	80
163	Functional exhaustion of antiviral lymphocytes in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 533-535.	4.8	1,450
164	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. <i>Blood Reviews</i> , 2020, 44, 100678.	2.8	38
165	NK cells mediate clearance of CD8 ⁺ T cellâ€™resistant tumors in response to STING agonists. <i>Science Immunology</i> , 2020, 5, .	5.6	128

#	ARTICLE	IF	CITATIONS
166	Distinct Human NK Cell Phenotypes and Functional Responses to Mycobacterium tuberculosis in Adults From TB Endemic and Non-endemic Regions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 120.	1.8	27
167	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 49.	1.8	122
168	NK Cell-Based Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2020, 11, 167.	2.2	211
169	Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2020, 19, 110.	7.9	295
170	New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1005-1023.	1.9	11
171	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
172	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5520-5533.	3.2	88
173	The two-faces of NK cells in oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 59-68.	3.2	20
174	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. <i>Cytokine and Growth Factor Reviews</i> , 2020, 52, 1-14.	3.2	18
175	Reverting Immune Suppression to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1554.	1.3	49
176	Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. <i>Pharmacological Research</i> , 2020, 155, 104691.	3.1	27
177	Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2020, 10, 301.	1.8	16
178	Unleashing Natural Killer Cells in the Tumor Microenvironmentâ€”The Next Generation of Immunotherapy?. <i>Frontiers in Immunology</i> , 2020, 11, 275.	2.2	101
179	Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 3038.	2.2	245
180	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	1.7	20
181	Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell. <i>Journal of Immunology Research</i> , 2020, 2020, 1-16.	0.9	12
182	CD155: A Multi-Functional Molecule in Tumor Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 922.	1.8	58
183	Harnessing natural killer cells for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 810-816.	0.6	43

#	ARTICLE	IF	CITATIONS
184	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. <i>Gastroenterology</i> , 2020, 159, 609-623.	0.6	100
185	Mechanism of tumor cells escaping from immune surveillance of NK cells. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 187-198.	1.1	17
186	Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?. <i>Cancers</i> , 2020, 12, 774.	1.7	10
187	Natural Killer Cells: Tumor Surveillance and Signaling. <i>Cancers</i> , 2020, 12, 952.	1.7	56
188	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	2.7	10
189	Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma. <i>Clinical and Experimental Immunology</i> , 2020, 201, 161-170.	1.1	25
190	Mechanisms of Resistance to NK Cell Immunotherapy. <i>Cancers</i> , 2020, 12, 893.	1.7	34
191	Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency. <i>Immunological Investigations</i> , 2021, 50, 338-355.	1.0	18
192	Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. <i>Hepatology</i> , 2021, 73, 1399-1418.	3.6	61
193	NK cells-directed therapies target circulating tumor cells and metastasis. <i>Cancer Letters</i> , 2021, 497, 41-53.	3.2	47
194	Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. <i>International Reviews of Immunology</i> , 2021, 40, 197-216.	1.5	8
195	The role of natural killer cell in gastrointestinal cancer: killer or helper. <i>Oncogene</i> , 2021, 40, 717-730.	2.6	54
196	Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 121-131.	1.9	37
197	Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. <i>Cancer Discovery</i> , 2021, 11, 45-58.	7.7	128
198	Tumor-Infiltrating Natural Killer Cells. <i>Cancer Discovery</i> , 2021, 11, 34-44.	7.7	223
199	Long non-coding RNAs: Emerging regulators for chemo/immunotherapy resistance in cancer stem cells. <i>Cancer Letters</i> , 2021, 500, 244-252.	3.2	22
200	Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	1.2	61
201	Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis. <i>Clinical and Experimental Immunology</i> , 2021, 204, 78-95.	1.1	10

#	ARTICLE	IF	CITATIONS
202	Emerging immunotherapies for metastasis. <i>British Journal of Cancer</i> , 2021, 124, 37-48.	2.9	32
203	Cancer Immunotherapy and the Nectin Family. <i>Annual Review of Cancer Biology</i> , 2021, 5, 203-219.	2.3	14
204	Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 12-22.	2.0	6
205	A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 134-140.	1.0	12
206	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
207	Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies. <i>Hematological Oncology</i> , 2021, 39, 11-19.	0.8	5
208	Exploring the NK cell platform for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 85-100.	12.5	605
209	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
210	CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 608404.	1.6	18
211	Checkpoint inhibition in the fight against cancer: NK cells have some to say in it. , 2021, , 267-304.		1
212	TIGIT ⁺ TIM-3 ⁺ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma. <i>OncImmunology</i> , 2021, 10, 1942673.	2.1	34
213	Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. <i>BMB Reports</i> , 2021, 54, 2-11.	1.1	36
214	Challenges for NK cell-based therapies: What can we learn from lymph nodes?. , 2021, , 33-51.		0
215	Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 612202.	2.2	66
216	Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. <i>BMB Reports</i> , 2021, 54, 44-58.	1.1	7
217	Targeting CD155 by radiocide-A overcomes tumour immuno-resistance to natural killer cells. <i>Pharmaceutical Biology</i> , 2021, 59, 47-53.	1.3	4
218	Clinical Detection of Peripheral Blood Natural Killer Cell Activity. <i>Journal of Biosciences and Medicines</i> , 2021, 09, 28-36.	0.1	0
219	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. <i>Cells</i> , 2021, 10, 56.	1.8	14

#	ARTICLE	IF	CITATIONS
220	NK Cells in Immunotherapy: How Important Are They?. , 2021, , 65-81.		0
221	Immunometabolic targeting of NK cells to solid tumors. , 2021, , 349-368.		0
222	NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms. , 2021, , 3-31.		2
223	The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies. , 2021, , 305-347.		0
224	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. , 2021, 5, 304-322.		2
225	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. <i>Oncolmunology</i> , 2021, 10, 1889822.	2.1	21
226	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. <i>Arthritis Research and Therapy</i> , 2021, 23, 15.	1.6	14
227	The Natural Killer“Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 621254.	2.2	33
228	Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer. <i>Aging</i> , 2021, 13, 5928-5945.	1.4	18
229	Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 9-26.	2.7	14
230	Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). <i>EBioMedicine</i> , 2021, 64, 103240.	2.7	22
231	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. <i>Cancers</i> , 2021, 13, 711.	1.7	18
232	TIGIT/CD226 Axis Regulates Anti-Tumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 200.	1.7	58
233	T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. <i>Cancers</i> , 2021, 13, 598.	1.7	19
234	Analysis of the Characteristics of TIGIT-Expressing CD3 ⁺ CD56 ⁺ NK Cells in Controlling Different Stages of HIV-1 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 602492.	2.2	8
235	Metabolism of Innate Immune Cells in Cancer. <i>Cancers</i> , 2021, 13, 904.	1.7	29
236	Dynamics of TIGIT and PD-1 expression on NK cells during the course of normal pregnancy. <i>Immunology Letters</i> , 2021, 230, 42-48.	1.1	5
237	Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT. <i>Cell Communication and Signaling</i> , 2021, 19, 12.	2.7	4

#	ARTICLE	IF	CITATIONS
238	TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2781-2793.	2.0	34
239	Anti-TIGIT differentially affects sepsis survival in immunologically experienced versus previously naive hosts. <i>JCI Insight</i> , 2021, 6, .	2.3	8
240	Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 1359.	5.8	64
241	Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. <i>Cancer Discovery</i> , 2021, 11, 1040-1051.	7.7	24
242	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4
244	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. <i>Stem Cell Research and Therapy</i> , 2021, 12, 200.	2.4	25
245	Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. <i>Biomarker Research</i> , 2021, 9, 15.	2.8	42
246	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021, 13, 1363.	1.7	24
247	Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. <i>Stem Cell Research and Therapy</i> , 2021, 12, 211.	2.4	33
248	Tâ€cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. <i>IUBMB Life</i> , 2021, 73, 726-738.	1.5	23
249	The Importance of Regulation in Natural Immunity to HIV. <i>Vaccines</i> , 2021, 9, 271.	2.1	2
250	Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 633685.	2.2	4
251	Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 961-974.	1.9	58
252	Natural Killer Cells: From Innate to Adaptive Features. <i>Annual Review of Immunology</i> , 2021, 39, 417-447.	9.5	85
254	Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. <i>Cancers</i> , 2021, 13, 1988.	1.7	14
255	Chronic stress physically spares but functionally impairs innate-like invariant Tâ€cells. <i>Cell Reports</i> , 2021, 35, 108979.	2.9	26
256	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 196.	1.8	18
257	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27

#	ARTICLE	IF	CITATIONS
258	Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1058.	1.8	17
259	CAR-NK Cells in the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5899.	1.8	69
260	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
261	Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRP α and TIGIT/PVR Pathways for Cancer Immuno-Therapy. <i>Biomolecules</i> , 2021, 11, 706.	1.8	21
262	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	1.6	76
263	Myeloma natural killer cells are exhausted and have impaired regulation of activation. <i>Haematologica</i> , 2021, 106, 2522-2526.	1.7	8
264	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. <i>Cancers</i> , 2021, 13, 2796.	1.7	13
265	The immune landscape of common CNS malignancies: implications for immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 729-744.	12.5	50
266	Limited Impact of the Inhibitory Receptor TIGIT on NK and T Cell Responses during <i>Toxoplasma gondii</i> Infection. <i>ImmunoHorizons</i> , 2021, 5, 384-394.	0.8	4
267	A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 660273.	1.3	6
268	Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 683381.	2.2	16
269	Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 100.	6.9	21
270	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. <i>International Immunology</i> , 2021, 33, 435-446.	1.8	14
271	Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1369.	1.8	6
272	Immune Circuits to Shape Natural Killer Cells in Cancer. <i>Cancers</i> , 2021, 13, 3225.	1.7	15
273	Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth. <i>Stem Cells International</i> , 2021, 2021, 1-17.	1.2	14
274	If small molecules immunotherapy comes, can the prime be far behind?. <i>European Journal of Medicinal Chemistry</i> , 2021, 218, 113356.	2.6	23
275	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 693609.	2.2	21

#	ARTICLE	IF	CITATIONS
276	The Adverse Impact of Tumor Microenvironment on NK-Cell. <i>Frontiers in Immunology</i> , 2021, 12, 633361.	2.2	21
277	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. <i>Chinese Medical Journal</i> , 2021, 134, 1780-1788.	0.9	7
278	Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 277-287.	2.0	27
279	Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6638.	1.8	5
280	Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. <i>Stem Cell Research and Therapy</i> , 2021, 12, 320.	2.4	31
281	Single-cell RNA sequencing in human lung cancer: Applications, challenges, and pathway towards personalized therapy. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 563-576.	0.6	7
282	SIRT2 promotes murine melanoma progression through natural killer cell inhibition. <i>Scientific Reports</i> , 2021, 11, 12988.	1.6	8
283	TIGIT-Fc Promotes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 1088-1097.	1.6	7
284	Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. <i>Viruses</i> , 2021, 13, 1450.	1.5	7
285	A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy. <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100935.	0.7	9
286	Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2022, 22, 173-181.	1.9	4
287	The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction. <i>Biochemical and Biophysical Research Communications</i> , 2021, 562, 9-14.	1.0	3
288	Combining single-cell sequencing to identify key immune genes and construct the prognostic evaluation model for colon cancer patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e465.	1.7	4
289	Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2083-2100.	4.8	40
290	Leveraging NKG2D Ligands in Immuno-Oncology. <i>Frontiers in Immunology</i> , 2021, 12, 713158.	2.2	56
291	The role of natural killer cells in liver inflammation. <i>Seminars in Immunopathology</i> , 2021, 43, 519-533.	2.8	19
292	TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 699895.	2.2	102
293	Towards efficient immunotherapy for bacterial infection. <i>Trends in Microbiology</i> , 2022, 30, 158-169.	3.5	41

#	ARTICLE	IF	CITATIONS
294	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 577-592.	1.6	27
295	Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry. <i>Frontiers in Immunology</i> , 2021, 12, 694055.	2.2	22
296	Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. <i>Cancers</i> , 2021, 13, 4263.	1.7	32
297	Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 267.	3.5	21
298	Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat. <i>Frontiers in Immunology</i> , 2021, 12, 701671.	2.2	15
299	NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100967.	2.7	7
300	Purinergic Receptor P2Y6 Is a Negative Regulator of NK Cell Maturation and Function. <i>Journal of Immunology</i> , 2021, 207, 1555-1565.	0.4	8
301	Prognostic value of natural killer cell activity for patients with HER2+ advanced gastric cancer treated with first-line fluoropyrimidine+platinum doublet plus trastuzumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 829-838.	2.0	7
302	Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells. <i>Nano Today</i> , 2021, 39, 101209.	6.2	8
303	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717038.	1.6	2
304	IFN γ signaling integrity in colorectal cancer immunity and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 23-32.	4.8	57
306	Engineering the next generation of CAR-NK immunotherapies. <i>International Journal of Hematology</i> , 2021, 114, 554-571.	0.7	37
307	NK Cell Therapy: A Rising Star in Cancer Treatment. <i>Cancers</i> , 2021, 13, 4129.	1.7	34
308	Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	5
309	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	1.8	7
310	Targeting natural killer cells to enhance vaccine responses. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 789-801.	4.0	29
311	A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3925-3934.	5.7	6
312	Involvement of TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With Liver <i>Echinococcus multilocularis</i> Infection. <i>Hepatology</i> , 2021, 74, 3376-3393.	3.6	22

#	ARTICLE	IF	CITATIONS
313	Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity. <i>International Immunopharmacology</i> , 2021, 98, 107837.	1.7	22
314	Natural killer cell-based immunotherapy for lung cancer: Challenges and perspectives (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14
315	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. <i>Journal of Cellular Physiology</i> , 2022, 237, 346-372.	2.0	13
316	A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10389.	1.8	14
317	High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. <i>Science Advances</i> , 2021, 7, eabg5016.	4.7	58
318	Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113860.	6.6	31
319	Identification of N6-Methyladenosine-Related lncRNAs for Subtype Identification and Risk Stratification in Gastric Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 725181.	1.3	9
320	TIGIT is a checkpoint of natural killer cell maturation and antitumor immunity. <i>Science Advances</i> , 2021, 7, eabi6515.	4.7	20
321	NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. <i>Frontiers in Immunology</i> , 2021, 12, 734551.	2.2	13
322	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
323	Immune Cycle-Based Strategies for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2107540.	7.8	24
324	TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. <i>Oral Oncology</i> , 2021, 121, 105472.	0.8	30
325	Innate Lymphoid Cells: New Targets for Cutaneous Squamous Cell Carcinoma Immunotherapy. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2320-2322.	0.3	2
326	Cutaneous Squamous Cell Carcinoma Development Is Associated with a Temporal Infiltration of ILC1 and NK Cells with Immune Dysfunctions. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2369-2379.	0.3	18
327	Natural Killer Cells in Cancer and Cancer Immunotherapy. <i>Cancer Letters</i> , 2021, 520, 233-242.	3.2	19
328	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. <i>Cancer Letters</i> , 2021, 521, 119-129.	3.2	16
329	Targeting natural killer cells in cancer immunotherapy. , 2022, , 63-82.		1
330	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0

#	ARTICLE	IF	CITATIONS
331	Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1893-1906.	2.0	7
332	CD226: a potent driver of antitumor immunity that needs to be maintained. <i>Cellular and Molecular Immunology</i> , 2022, 19, 969-970.	4.8	7
333	Exploiting the CRISPR-Cas9 gene editing system for human cancers and immunotherapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1286.	1.7	11
334	Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities. , 2021, , 405-437.		0
335	PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2021, 27, 1932-1940.	3.2	25
336	Î±-Pinene Enhances the Anticancer Activity of Natural Killer Cells via ERK/AKT Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 656.	1.8	38
337	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	1.5	25
338	High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells. <i>Methods in Molecular Biology</i> , 2021, 2194, 255-290.	0.4	2
339	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
340	Artemisinin sensitizes tumor cells to NK cell-mediated cytotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 418-423.	1.0	14
341	Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1Î± Unleashes NK Cell Activity. <i>Immunity</i> , 2020, 52, 1075-1087.e8.	6.6	167
342	Cancer cells educate natural killer cells to a metastasis-promoting cell state. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	85
345	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
346	Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. <i>JCI Insight</i> , 2020, 5, .	2.3	27
347	Discovery of specialized NK cell populations infiltrating human melanoma metastases. <i>JCI Insight</i> , 2019, 4, .	2.3	81
348	Killers 2.0: NK cell therapies at the forefront of cancer control. <i>Journal of Clinical Investigation</i> , 2019, 129, 3499-3510.	3.9	166
349	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	3.9	90
350	Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma. <i>Aging</i> , 2019, 11, 5463-5482.	1.4	20

#	ARTICLE	IF	CITATIONS
351	Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. <i>Cancer Biology and Medicine</i> , 2020, 17, 1026-1038.	1.4	26
352	Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma. <i>Current Drug Targets</i> , 2020, 21, 1606-1612.	1.0	4
353	Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2019, 10, 3080.	2.2	14
354	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
355	Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 3871.	1.7	17
356	Gastrointestinal cancer stem cells as targets for innovative immunotherapy. <i>World Journal of Gastroenterology</i> , 2020, 26, 1580-1593.	1.4	9
357	High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2020, 44, 2056-2066.	1.2	3
358	Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN- γ Production, Dichotomous to TIGIT, in HIV-1 Infection. <i>ImmunoHorizons</i> , 2019, 3, 531-546.	0.8	31
359	Cancer immunotherapy by targeting immune checkpoint receptors. <i>World Journal of Immunology</i> , 2018, 8, 1-11.	0.5	4
360	CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1986943.	2.1	0
361	Expression Regulation and Function of T-Bet in NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 761920.	2.2	23
362	The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11385.	1.8	7
363	Activation of Cascade-Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102080.	3.9	5
364	Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?. <i>Vaccines</i> , 2021, 9, 1144.	2.1	4
365	Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. <i>Advanced Science</i> , 2021, 8, e2101672.	5.6	36
366	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 751183.	1.3	10
367	The GPR171 pathway suppresses T cell activation and limits antitumor immunity. <i>Nature Communications</i> , 2021, 12, 5857.	5.8	11
369	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0

#	ARTICLE	IF	CITATIONS
370	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164.		0
371	Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 387-407.	2.7	9
372	Simultaneous blockade of TIGIT and HIF-1 α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. <i>International Immunopharmacology</i> , 2021, 101, 108288.	1.7	22
373	Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer. <i>International Immunopharmacology</i> , 2021, 101, 108302.	1.7	1
374	An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade. <i>International Immunopharmacology</i> , 2021, 101, 108307.	1.7	7
375	Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease. , 2020, , 297-318.		0
377	Role of NKG2D and its ligands in cancer immunotherapy. <i>American Journal of Cancer Research</i> , 2019, 9, 2064-2078.	1.4	37
378	Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750022.	1.8	18
379	Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12919.	1.8	27
380	A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment. <i>Scientific Reports</i> , 2021, 11, 22502.	1.6	23
381	Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 767466.	1.8	13
382	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102492.	1.7	4
383	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11
384	Innate tumor killers in colorectal cancer. <i>Cancer Letters</i> , 2022, 527, 115-126.	3.2	11
385	Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 730970.	2.2	6
386	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
387	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24259.	0.9	10
388	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121527.	2.6	16

#	ARTICLE	IF	CITATIONS
389	High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. <i>Cancers</i> , 2022, 14, 221.	1.7	21
390	Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects. <i>Aging</i> , 2022, 14, 1048-1064.	1.4	15
391	NF- κ B-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-30.	0.9	1
392	Structural and functional characterization of a monoclonal antibody blocking TIGIT. <i>MAbs</i> , 2022, 14, 2013750.	2.6	6
393	Identification of Circular RNA-Based Immunomodulatory Networks in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 779706.	1.3	3
394	Innate Immunity and Cancer Pathophysiology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 425-457.	9.6	41
395	Harnessing natural killer cells for the treatment of multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 69-85.	0.8	12
396	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing \hat{I}^{31} T cells. <i>Nature Communications</i> , 2022, 13, 231.	5.8	14
397	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85
398	Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). <i>Journal of Clinical Pathology</i> , 2022, 75, 217-221.	1.0	9
399	Preclinical and exploratory human studies of novel ^{68}Ga -labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2584-2594.	3.3	12
400	Oral-Intestinal Microbiota in Colorectal Cancer: Inflammation and Immunosuppression. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 747-759.	1.6	19
401	Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 542-565.	4.3	51
402	LLT1-CD161 Interaction in Cancer: Promises and Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 847576.	2.2	15
403	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
404	Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas. <i>Scientific Reports</i> , 2022, 12, 1872.	1.6	0
405	Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 62.	3.5	44
406	TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection. <i>Frontiers in Medicine</i> , 2021, 8, 816474.	1.2	6

#	ARTICLE	IF	CITATIONS
407	CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells. <i>Frontiers in Immunology</i> , 2022, 13, 840457.	2.2	14
408	Harnessing radiotherapy-induced NK-cell activity by combining DNA damage response inhibition and immune checkpoint blockade. , 2022, 10, e004306.		36
409	Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 844260.	1.3	7
410	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	2.2	13
411	Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 858905.	1.1	2
412	CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2022, 208, 220-232.	1.1	6
413	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. <i>Immunity</i> , 2022, 55, 512-526.e9.	6.6	118
414	Biology and Clinical Relevance of HCMV-Associated Adaptive NK Cells. <i>Frontiers in Immunology</i> , 2022, 13, 830396.	2.2	4
415	Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin. <i>Frontiers in Immunology</i> , 2022, 13, 842831.	2.2	6
416	The changing role of natural killer cells in cancer metastasis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	36
417	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
418	NK cell exhaustion, B cell exhaustion and T cell exhaustion—the differences and similarities. <i>Immunology</i> , 2022, 166, 155-168.	2.0	39
419	CAR-NK cells for cancer immunotherapy: from bench to bedside. <i>Biomarker Research</i> , 2022, 10, 12.	2.8	65
420	Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 822298.	2.2	13
421	Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 559-577.	21.5	68
422	Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses. <i>Clinical and Experimental Medicine</i> , 2023, 23, 411-425.	1.9	2
423	Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. <i>Molecular Immunology</i> , 2022, 144, 58-70.	1.0	23
424	TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. , 2022, 10, e004711.		69

#	ARTICLE	IF	CITATIONS
425	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13
426	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. <i>Clinical and Translational Medicine</i> , 2022, 12, e794.	1.7	13
427	Natural killer cell therapy: A new frontier for obesity-associated cancer. <i>Cancer Letters</i> , 2022, 535, 215620.	3.2	17
429	Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. <i>Cells</i> , 2022, 11, 116.	1.8	9
430	An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. , 2021, 9, e002843.		29
431	Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. <i>Diagnostics</i> , 2021, 11, 2370.	1.3	6
432	Single-cell RNA-sequencing reveals distinct immune cell subsets and signaling pathways in IgA nephropathy. <i>Cell and Bioscience</i> , 2021, 11, 203.	2.1	11
433	CAR-NK Cells: From Natural Basis to Design for Kill. <i>Frontiers in Immunology</i> , 2021, 12, 707542.	2.2	50
434	Identification of Subtypes and a Prognostic Gene Signature in Colon Cancer Using Cell Differentiation Trajectories. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705537.	1.8	7
435	Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?. <i>Clinical and Translational Science</i> , 2022, 15, 1091-1103.	1.5	4
436	Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 164.	1.8	14
437	Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. <i>Frontiers in Immunology</i> , 2021, 12, 778329.	2.2	26
438	Cutting edge: the regulatory mechanisms of macrophage polarization and function during pregnancy. <i>Journal of Reproductive Immunology</i> , 2022, 151, 103627.	0.8	14
439	Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 862527.	2.2	23
440	Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells. <i>Journal of Immunology Research</i> , 2022, 2022, 1-19.	0.9	7
441	Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 98.	7.9	36
442	The tricks for fighting against cancer using CAR NK cells: A review. <i>Molecular and Cellular Probes</i> , 2022, 63, 101817.	0.9	5
455	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117065119.	3.3	26

#	ARTICLE	IF	CITATIONS
456	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	3.2	36
458	The TOX subfamily: all-round players in the immune system. <i>Clinical and Experimental Immunology</i> , 2022, 208, 268-280.	1.1	4
459	<i>Candida albicans</i> evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT. <i>Nature Communications</i> , 2022, 13, 2463.	5.8	10
460	Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2022, 12, 1886-1903.	7.7	31
461	NK Cells and ILC1s in Cancer Biology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1365, 41-55.	0.8	2
462	Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. , 2022, 10, e004244.		23
463	Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. <i>Nature Reviews Immunology</i> , 2023, 23, 90-105.	10.6	110
464	Turning cold tumors hot: from molecular mechanisms to clinical applications. <i>Trends in Immunology</i> , 2022, 43, 523-545.	2.9	176
465	Natural killer cells: a promising immunotherapy for cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	56
466	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	5
467	<scp>TIGIT</scp> / <scp>CD47</scp> dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 0, , .	0.8	4
468	Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
469	TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022, 41, 157-162.	0.8	0
470	Cell-based drug delivery systems and their in vivo fate. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114394.	6.6	28
471	Emergence of the CD226 Axis in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
472	Tumor Microenvironmentâ€™A Short Review of Cellular and Interaction Diversity. <i>Biology</i> , 2022, 11, 929.	1.3	22
473	What Inhibits Natural Killersâ€™™ Performance in Tumour. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7030.	1.8	2
474	Identification of a differentiation-related prognostic nomogram based on single-cell RNA sequencing in clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
475	TGFÎ² and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 1047-1054.	1.6	11
476	TIGIT as a Novel Prognostic Marker for Immune Infiltration in Invasive Breast Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 639-651.	0.6	5
477	In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	26
478	Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
479	Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
480	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7859.	1.8	10
482	The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, , 100373.	0.6	1
483	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
484	Discovery of TIGIT inhibitors based on DEL and machine learning. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
485	Immune Checkpoint Inhibitors in Cancer Therapyâ€”How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18
486	CD155 in tumor progression and targeted therapy. <i>Cancer Letters</i> , 2022, 545, 215830.	3.2	11
487	Natural killer cells: the next wave in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
488	Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing. <i>Cancer Biology and Medicine</i> , 0, , 1-18.	1.4	2
489	Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
490	Natural killer cells and bone marrow mesenchymal stem cells: A dangerous liaison in multiple myeloma. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
491	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. <i>Cells</i> , 2022, 11, 2351.	1.8	29
492	Immunotherapy: Reshape the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	77
493	TIGIT blockade enhances tumor response to radiotherapy via a CD103â€™+â€™dendritic cell-dependent mechanism. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 193-209.	2.0	10

#	ARTICLE	IF	CITATIONS
494	DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
495	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
496	The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	4
497	Blockade of Tâ€cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBVâ€related HCC in mice. <i>Hepatology</i> , 2023, 77, 965-981.	3.6	12
498	Evasion of NK cell immune surveillance via the vimentin-mediated cytoskeleton remodeling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
499	A <scp>hypoxiaâ€related lncRNA</scp> model for prediction of head and neck squamous cell carcinoma prognosis. <i>Cancer Medicine</i> , 0, , .	1.3	2
500	Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches. <i>Pharmaceutics</i> , 2022, 14, 1721.	2.0	10
501	Functional crosstalk and regulation of natural killer cells in tumor microenvironment: Significance and potential therapeutic strategies. <i>Genes and Diseases</i> , 2023, 10, 990-1004.	1.5	4
502	The Features of Checkpoint Receptorâ€Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. <i>Biomedicines</i> , 2022, 10, 2081.	1.4	3
503	Unleashing Anti-Tumor Activity of Natural Killer Cells Via Modulation of Immune Checkpoints Receptors and Molecules. , 0, 8, 463-471.		1
504	Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. <i>Clinical Lung Cancer</i> , 2022, 23, 643-658.	1.1	5
505	Immune cellular components and signaling pathways in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 187-201.	4.3	18
506	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
507	Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
508	PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma. <i>Translational Oncology</i> , 2022, 24, 101501.	1.7	5
509	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. <i>Seminars in Cancer Biology</i> , 2022, 86, 14-27.	4.3	21
510	NK cell immunometabolism as target for liver cancer therapy. <i>International Immunopharmacology</i> , 2022, 112, 109193.	1.7	3
511	Molecular imaging of immune checkpoints in oncology: Current and future applications. <i>Cancer Letters</i> , 2022, 548, 215896.	3.2	5

#	ARTICLE	IF	CITATIONS
512	Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomarker Research, 2022, 10, .	2.8	22
513	Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance. Cancer Treatment and Research Communications, 2022, 33, 100643.	0.7	3
514	Biological and Clinical Aspects of Metastatic Spinal Tumors. Cancers, 2022, 14, 4599.	1.7	11
515	Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy. Pharmaceutical Fronts, 2022, 04, e197-e206.	0.4	0
516	Systemic Sclerosis Association with Malignancy. Clinical Reviews in Allergy and Immunology, 2022, 63, 398-416.	2.9	7
517	Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer. Drug Design, Development and Therapy, 0, Volume 16, 3055-3070.	2.0	6
518	V-Set and immunoglobulin domain containing (VSIg) proteins as emerging immune checkpoint targets for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	3
519	Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants. Cancers, 2022, 14, 4548.	1.7	2
520	Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?. Cancers, 2022, 14, 4439.	1.7	6
521	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 0, 13, .	2.2	6
522	Human natural killer cells: Form, function, and development. Journal of Allergy and Clinical Immunology, 2023, 151, 371-385.	1.5	14
523	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	33
524	Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. Cell Communication and Signaling, 2022, 20, .	2.7	3
525	Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer. Frontiers in Immunology, 0, 13, .	2.2	6
526	Ginsenosides: Allies of gastrointestinal tumor immunotherapy. Frontiers in Pharmacology, 0, 13, .	1.6	3
527	Tissue-resident CD69 ⁺ CXCR6 ⁺ Natural Killer cells with exhausted phenotype accumulate in human non-small cell lung cancer. European Journal of Immunology, 2022, 52, 1993-2005.	1.6	3
528	Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion. International Journal of Molecular Sciences, 2022, 23, 11789.	1.8	11
529	Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	54

#	ARTICLE	IF	CITATIONS
530	Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
531	Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 5046.	1.7	8
532	Impaired intratumoral natural killer cell function in head and neck carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
533	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. <i>Cells</i> , 2022, 11, 3147.	1.8	3
534	Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
535	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
536	Tolerogenic dendritic cells alleviate collagen α 1-induced arthritis by forming microchimerism and affecting the expression of immune checkpoint molecules. <i>European Journal of Immunology</i> , 2022, 52, 1980-1992.	1.6	4
537	Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. <i>Seminars in Immunology</i> , 2022, 61-64, 101660.	2.7	4
538	VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. <i>Life Sciences</i> , 2022, 310, 121083.	2.0	19
539	Exosomal circRNAs: A key factor of tumor angiogenesis and therapeutic intervention. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113921.	2.5	2
540	Weaponizing natural killer cells for solid cancer immunotherapy. <i>Trends in Cancer</i> , 2023, 9, 111-121.	3.8	5
541	Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1153-1167.	2.0	4
542	TIGIT α -expressing zoledronate α -specific γ T cells display enhanced antitumor activity. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	1
543	The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
544	Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
545	The landscape of TIGIT target and clinical application in diseases. , 2022, 1, .		0
546	The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 5757.	1.7	10
547	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. <i>Annual Review of Immunology</i> , 2023, 41, 17-38.	9.5	30

#	ARTICLE	IF	CITATIONS
548	PVRâ€™A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 2953.	1.3	1
549	N6-methyladenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
550	Allogeneic natural killer cell therapy. <i>Blood</i> , 2023, 141, 856-868.	0.6	33
551	Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
552	High-Throughput and Efficient Intracellular Delivery Method via a Vibration-Assisted Nanoneedle/Microfluidic Composite System. <i>ACS Nano</i> , 2023, 17, 2101-2113.	7.3	6
553	<sc>NR4A1</sc> mediates <sc>NK</sc>â€™cell dysfunction in hepatocellular carcinoma via the <sc>IFN</sc>â€™3/<sc>pâ€™STAT1</sc>/<sc>IRF1</sc> pathway. <i>Immunology</i> , 2023, 169, 69-82.	2.0	6
554	CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer. <i>Cancers</i> , 2023, 15, 117.	1.7	7
555	NKG2D engagement on human NK cells leads to DNAMâ€™1 hypoâ€™responsiveness through different converging mechanisms. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	4
556	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
557	TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
558	Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. <i>International Journal of Molecular Sciences</i> , 2023, 24, 204.	1.8	0
559	The effect of Wnt/Î²-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. <i>Oncology Research</i> , 2022, 30, 99-116.	0.6	7
560	Contribution of natural killer cells in innate immunity against colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
561	Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	14
562	Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
563	Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. <i>Science Advances</i> , 2023, 9, .	4.7	3
564	Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 14, 1-9.	1.3	6
565	NOD-<i>scid</i> IL2rÎ³null</i> mice lacking TLR4 support human immune system development and the study of human-specific innate immunity. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
566	Insights into the tumor microenvironment of B cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
567	Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. <i>Cancer Communications</i> , 2023, 43, 177-213.	3.7	8
568	Tumor immunology. , 2023, , 245-452.		0
569	Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells. , 2023, , 3-25.		1
570	The inhibitory NKR-P1B receptor regulates NK cell-mediated mammary tumor immunosurveillance in mice. <i>OncImmunology</i> , 2023, 12, .	2.1	1
571	Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
573	Natural killer cells as immunotherapeutic effectors for solid tumors. , 2023, , 65-81.		0
574	The Immunoregulatory Effect of Aconite Treatment on H22 Tumor-Bearing Mice via Modulating Adaptive Immunity and Natural Killer-Related Immunity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2023, 2023, 1-10.	0.5	2
575	Combining radiotherapy and NK cell-based therapies: The time has come. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1
576	<i>TIPE2</i> deletion improves the therapeutic potential of adoptively transferred NK cells. , 2023, 11, e006002.		5
577	ICI-based therapies: A new strategy for oral potentially malignant disorders. <i>Oral Oncology</i> , 2023, 140, 106388.	0.8	2
578	Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 29, 173-184.	1.8	5
579	Mycosis Fungoides and SÅ©zary Syndrome: Microenvironment and Cancer Progression. <i>Cancers</i> , 2023, 15, 746.	1.7	2
580	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
581	The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56bright NK cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
582	Checkpoint <i>TIPE2</i> Limits the Helper Functions of NK Cells in Supporting Antitumor CD8 ⁺ T Cells. <i>Advanced Science</i> , 2023, 10, .	5.6	6
583	Single-cell RNA sequencing in orthopedic research. <i>Bone Research</i> , 2023, 11, .	5.4	6
584	Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. , 2023, , .		1

#	ARTICLE	IF	CITATIONS
585	Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
586	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
587	Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2023, 636, 122810.	2.6	2
588	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancerâ€™Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	1.7	4
589	A Nanotherapeutic Strategy to Reverse NK Cell Exhaustion. <i>Advanced Materials</i> , 2023, 35, .	11.1	7
590	Inhibition of hepatic natural killer cell function via the TIGIT receptor in schistosomiasis-induced liver fibrosis. <i>PLoS Pathogens</i> , 2023, 19, e1011242.	2.1	3
591	Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
592	EBV-Upregulated B7-H3 Inhibits NK cellâ€™Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. <i>Cancer Immunology Research</i> , 2023, 11, 830-846.	1.6	4
593	Targeting the Molecular and Immunologic Features of Leiomyosarcoma. <i>Cancers</i> , 2023, 15, 2099.	1.7	5
594	In Situ STINGâ€™Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Antiâ€™PDâ€™1â€™Resistant Tumors. <i>Advanced Materials</i> , 2023, 35, .	11.1	2
595	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
596	The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. <i>Cancers</i> , 2023, 15, 2323.	1.7	14
597	Innate lymphoid cells and innate-like T cells in cancerâ€™ at the crossroads of innate and adaptive immunity. <i>Nature Reviews Cancer</i> , 2023, 23, 351-371.	12.8	15
620	Natural Killer Cells: A Promising Cellular Therapy Platform to Conquer Cancer. , 2024, , 403-410.		0
631	Dual impact of radiation therapy on tumor-targeting immune responses. <i>International Review of Cell and Molecular Biology</i> , 2023, , xiii-xxiv.	1.6	0
655	Systemic Oncosphere: Host Innate Immune System. , 2023, , 419-442.		0
657	Significance of NK Cell in Cancer. , 2023, , 1-19.		0
665	Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
696	Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery, 2024, 10, .	2.0	1
703	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American Journal of Clinical Dermatology, 0, , .	3.3	0